久久国产中文娱乐网_日韓一級高清_a级毛片黄免费观看m_宝贝对着摄像头自己做忘羡_亚洲黄色天堂网_高清有码巨乳日本在线_俄罗斯6一12呦女精品不卡_欧美日批在线观看视频_最近中文字幕更新免費_粉嫩虎白女P虎白女在线

The OSD Facility Relocation Groundbreaking Ceremony of Eisai China Inc. (hereinafter referred to as “Eisai China”) was held at Suzhou Industrial Park on the morning of May 31, 2016. The leaders of the Japanese Consulate General in Shanghai, Jiangsu Provincial Food and Drug Administration, Suzhou Municipal Government, Management Committee of Suzhou Industrial Park, Suzhou Municipal Food and Drug Administration, Eisai Co., Ltd., and Eisai China attended the groundbreaking ceremony.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that its European regional headquarters Eisai Europe Ltd. (Location: U.K.) has received a positive opinion from the European Medicines Agency‘s Committee for Medicinal Products for Human Use (CHMP) on anticancer agent Halaven? (eribulin mesylate) for treatment of adult patients with unresectable liposarcomas who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease. Halaven is the first and only single agent to demonstrate an overall survival (OS) benefit in a Phase III trial in patients with advanced, recurrent or metastatic soft tissue sarcoma (liposarcoma or leiomyosarcoma). Following approval for use in the treatment of metastatic breast cancer in the EU, this marks the second indication for which Halaven has received a positive CHMP opinion based on a statistically significant extension of OS.

On a stormy day on Sep.?2,?2014?as predicated by the Meteorological Forecast and Warning Center of Beijing, the staff of Eisai Pharmacy Administration Base was preparing for the “Well-being Campaign” donation to Yunzhou Central Primary School in Chicheng County with full enthusiasm and expectation. Upon entrustment by Feng Yanhui, general manager of Eisai China, the staff, all filled with the “hhc” spirit, embarked on the journey to Yunzhou Central Primary School just before dawn in spite of the rain.

The “Meet You on Wednesdays” platform sponsored by China International Forum of Medicine under Chinese Medical Association and co-sponsored by Eisai China Inc. was officially launched recently. It is a network interaction & learning platform on peripheral neuropathy and other relevant diseases. China International Forum of Medicine is responsible for inviting prestigious national neurologist to deliver lectures and introduce typical cases of peripheral neuropathy, aiming at improving the skills of clinicians’ of all levels in Mainland China in diagnosis and treatment of peripheral neuropathy.

Osteoporosis is a latent and degenerative disease featured by high morbidity, disability rate and fatality rate. 69,440,000 persons of those aged 50 or above suffer from osteoporosis.?The fatalness of osteoporotic fracture is 40% for women and 13% for men. For those suffering from osteoporotic fragility fracture on hip, 20% will die from complications of this disease, 30% become permanently disable, 40% lose the ability of independent ambulation, and 50% lose the ability of self-care after one year. Meanwhile, medical staff serving those patients has to work for long hours under tremendous pressure.?What’s more, physicians are also victims of diseases. They are exposed to twice higher risk of diseases than the peers. In particular, the physicians aged 40 or above are exposed to a much higher risk of geriatric diseases than average. The medical staff who brings health and happiness to patients also requires our concern and care.